8 completed, 3 recruiting, 2 active not recruiting, 2 terminated. 7 Phase 2, 6 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Terminated 2, Active not recruiting 1 |
| Phase 1 | 6 | Active not recruiting 2, Completed 2, Terminated 2 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Stage IV Prostate Cancer AJCC v7: new trials by email Literature Review of Stage IV Prostate Cancer AJCC v7 trials Research Report on Stage IV Prostate Cancer AJCC v7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection Questionnaire Administration, Biospecimen Collection - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Recruiting | Alliance for Clinical Trials in Oncology | 2900 | 2022-08-18 | 2026-10-28 | |
| Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer Biospecimen Collection, Electronic Health Record Review, Quality-of-Life Assessment - Stage I Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7 | Recruiting | City of Hope Medical Center | 30 | 2021-02-25 | 2026-10-16 | |
| Fatigue Interventions in Cancer (Exercise Intervention) Cognitive Behavior Therapy, Exercise Intervention - Sedentary Lifestyle, Stage III Prostate Cancer AJCC v7 | Phase 2 | Completed | University of Utah | 126 | 2018-02-26 | 2026-02-17 |
| Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer CT (Computed Tomography), Gallium Ga 68-DOTATATE, Positron Emission Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Completed | Emory University | 17 | 2018-02-22 | 2025-07-17 |
| A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy Abiraterone Acetate, Apalutamide, Degarelix - Stage III Prostate Adenocarcinoma AJCC v7, Stage III Prostate Cancer AJCC v7 | Phase 2 | Completed | University of Washington | 22 | 2017-03-09 | 2022-01-13 |
| 68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography - Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7 | Not applicable | Completed | Jonsson Comprehensive Cancer Center | 400 | 2016-12-12 | 2023-04-12 |
| Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Carboplatin, Docetaxel, Laboratory Biomarker Analysis - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 / Phase 2 | Terminated | University of Washington | 28 | 2016-02-29 | 2021-10-01 |
| Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression Enzalutamide, Ribociclib, Laboratory Biomarker Analysis - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 52 | 2015-12-01 | 2026-04-22 |
| Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Cabazitaxel, Enzalutamide, Laboratory Biomarker Analysis - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 / Phase 2 | Active not recruiting | OHSU Knight Cancer Institute | 37 | 2015-08-13 | 2026-09-15 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Pharmacological Study, Romidepsin - Glioma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-08-03 | 2025-02-07 |
| Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Abiraterone Acetate, Laboratory Biomarker Analysis, Prednisone - Castration-Resistant Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 159 | 2012-03-30 | 2020-11-12 |
| Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Akt Inhibitor MK2206, Hydroxychloroquine - Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 62 | 2011-11-23 | 2026-09-09 |
| Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Localized Renal Pelvis and Ureter Urothelial Carcinoma, Malignant Solid Neoplasm | Recruiting | University of Washington | 1500 | 2009-08-01 | 2026-08-06 | |
| Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Bevacizumab, Cisplatin, Gemcitabine Hydrochloride - Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 506 | 2009-07-15 | 2026-06-24 |
| Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7 | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2003-05-13 | 2020-07-30 |
Prostatic Neoplasms (15) · Carcinoma, Renal Cell (3) · Melanoma (3) · Urinary Bladder Neoplasms (3) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lung Neoplasms (2) · Carcinoma, Transitional Cell (1) · Esophageal Neoplasms (1) · Glioma (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1)
Genital Diseases (15) · Genital Diseases, Male (15) · Genital Neoplasms, Male (15) · Male Urogenital Diseases (15) · Neoplasms (15) · Neoplasms by Site (15) · Prostatic Diseases (15) · Urogenital Diseases (15) · Urogenital Neoplasms (15) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Urologic Diseases (5) · Urologic Neoplasms (5) · Carcinoma (4) · Neoplasms by Histologic Type (4)
Magnetic Resonance Spectroscopy (3) · Prednisone (3) · deltacortene (3) · prednylidene (3) · Abiraterone Acetate (2) · enzalutamide (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 68Ga-DKFZ-PSMA-11 (1) · Bevacizumab (1) · Biopsy (1) · CTLA-4 Antigen (1) · Carboplatin (1) · Cisplatin (1) · Cognitive Behavioral Therapy (1) · Colony-Stimulating Factors (1)
National Cancer Institute (NCI) (5) · University of Washington (3) · Alliance for Clinical Trials in Oncology (1) · City of Hope Medical Center (1) · Emory University (1) · Jonsson Comprehensive Cancer Center (1) · OHSU Knight Cancer Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Utah (1)
United States (15) · Canada (1) · Puerto Rico (1)
Eric J Small (1) · Johannes Czernin (1) · Jonathan E Rosenberg (1) · Julie N Graff (1) · Jyoti Malhotra (1) · Maha H Hussain (1) · Marie Wood, MD (1) · Mehmet Asim Bilen, MD (1) · Michael Schweizer (1) · Robert B. Montgomery (1) · Robert Montgomery (1) · Roisin M Connolly (1) · Tanya B Dorff (1) · Umang Swami, MD (1) · William Kevin Kelly, MD (1)
PMID 18523152, PMID 29261439, PMID 32376721, PMID 32958451, PMID 33602654, PMID 33989025, PMID 34529005, PMID 34649942, PMID 37482512, PMID 39863139, PMID 40256659, PMID 40591902, PMID 41499420
P50CA097186 (3), UM1CA186716 (3), P30CA015704 (2), U01CA070095 (2), UM1CA186691 (2), N01CM00038 (1), N01CM00039 (1), N01CM00071 (1), P30CA014599 (1), P30CA033572 (1), P30CA072720 (1), U01CA062491 (1), U01CA062505 (1), U01CA069912 (1), U01CA132123 (1)